✦ LIBER ✦

A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: Should ezetimibe move to the “Back of the Line” as a therapy for dyslipidemia?

✍ Scribed by Peter P. Toth; Kevin C. Maki

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Implications of the Ezetimibe and Si

✍ Kiran Musunuru; Roger S. Blumenthal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

Comparison of ezetimibe plus simvastatin

✍ John J.P. Kastelein; Philip T. Sager; Eric de Groot; Enrico Veltri 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 270 KB

Changes in prescription patterns before

✍ Peter P. Toth; Christie M. Ballantyne; Michael H. Davidson; Joanne E. Tomassini; 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 392 KB